The clinical utility of a heterologous radioimmunoassay for human prolactin.
A specific and sensitive double antibody radioimmunoassay for human prolactin has been developed utilizing anti-human prolactin and purified ovine prolactin for radioiodination. Employing this radioimmunoassay, as little as 1.5 ng of prolactin can be quantified in a ml of human serum. The prolactin in serum detected by the radioimmunoassay behaved in a similar manner to purified human 125-I-labled prolactin on polyacrylamide gel electrophoresis. Exogenous prolactin could be completely recovered when varying amounts were added to a constant volume of serum. In normal control and primary hypothyroid subjects, intravenous administration of thyrotropin-releasing hormone elicited a peak prolactin response 30 min post-injection. Hyperthyroid and hypopituitary subjects did not manifest a significant increase in serum prolactin concentration after the injection. Subjects with functional galactorrhea had high resting prolactin levels and exhibited peak increase in serum prolactin concentration at 60 min following the administration of thyrotropin-releasing hormone.
D000818:Animals; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005687:Galactorrhea / Q000503:physiopathology; D006111:Graves Disease / Q000503:physiopathology; D006801:Humans; D007018:Hypopituitarism / Q000503:physiopathology; D007037:Hypothyroidism / Q000503:physiopathology; D007457:Iodine Radioisotopes; D008297:Male; D011247:Pregnancy; D011388:Prolactin / Q000097:blood* / Q000276:immunology; D011863:Radioimmunoassay / Q000379:methods; D012756:Sheep; D013973:Thyrotropin-Releasing Hormone
D007457:Iodine Radioisotopes; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin